Back to search

Switzerland· 68143005

Pemazyre 13,5 mg, comprimés

A pemigatinib product containing pemigatinibum, registered in Switzerland by Incyte Biosciences International Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EN02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedPemazyre 13,5 mg, comprimésATCL01EN02REGISTER NO.68143005PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Pemigatinib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EN02 (pemigatinib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Pemigatinib · ATC L01EN02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pemigatinib costs, country by country.

Normalised to the WHO defined daily dose (9 mg), so markets compare like for like.

  • Switzerland: $1227.26 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Pemigatinib · price per daily dose (9 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1227.26
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
pemigatinibum
Manufacturer
Incyte Biosciences International Sàrl
Country
Switzerland (CH)
ATC code
L01EN02
ATC class
Pemigatinib
Defined daily dose
9 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680681430056
    Blist 14 Stk
    CHF 7124.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

71 interactions on record for pemigatinib.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pemigatinib · interactions on record

71 records

  • 30 severe
  • 41 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ChloramphenicolJ01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pemigatinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pemigatinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pemazyre
  • Liechtenstein · Pemazyre
  • Norway · Pemazyre

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/744666ee-f434-4c27-b4cf-1020b8b47ca4
GET /v1/drugs/744666ee-f434-4c27-b4cf-1020b8b47ca4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "pemigatinibum 13.5 mg",
  "valid_from": "2026-08-01",
  "limitations": "[{\"description\":\"Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nPEMAZYRE wird als Monotherapie zur Behandlung von Erwachsenen mit lokal fortgeschrittenem, inoperablem oder metastasiertem Cholangiokarzinom mit einer Fibroblasten-Wachstumsfaktor-Rezeptor-2 (FGFR2)-Fusion oder einem FGFR2-Rearrangement, das nach mindestens einer vorgängigen systemischen Therapielinie fortgeschritten ist, vergütet.<br>\\nDie FGFR2-Fusion oder das FGFR2-Rearrangement ist vor der Behandlung mit PEMAZYRE mit einer geeigneten Methode nachzuweisen.<br> \\nPatienten mit unbehandelten oder fortgeschrittenen Hirn-/ZNS Metastasen sind von der Vergütung einer Behandlung mit PEMAZYRE ausgeschlossen.<br> \\nDie Behandlung mit PEMAZYRE erfolgt bis zur Progression der Erkrankung oder bis zum Auftreten inakzeptabler Toxizität.<br> \\nEine Rotation innerhalb der FGFR-Inhibitoren wird ausschliesslich bei Kontraindikation oder Unverträglichkeit vergütet.<br>\\n<br>\\nDie Zulassungsinhaberin Incyte Biosciences International Sàrl vergütet die ersten 2 bezogenen Packungen PEMAZYRE auf Aufforderung desjenigen Krankenversicherers, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, zum aktuellen FAP vollständig zurück. Die Zulassungsinhaberin Incyte Biosciences International Sàrl erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin zudem für jede zusätzlich bezogene Packung PEMAZYRE einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21303.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21303.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-07-01\",\"validTo\":\"2027-01-31\"}]",
  "galenic_form": "Tabl 13.5 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-11-01",
  "self_retention_pct": 10
}

See everything about pemigatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.